Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Risk/Benefit from Adjuvant Chemo for Early Stage NSCLC: Maturing Data Help Us Discriminate Likely Beneficiaries
Author
Howard (Jack) West, MD

Over the last 5 years, it’s become standard to consider and often recommend post-operative chemotherapy to patients with higher risk, early stage lung cancer in order to reduce the risk of it recurring and increase the cure rate. In that time, we’ve also seen that there are subgroups of patients who may be harmed by chemo. This may be because their risk of recurrence is not high enough to justify the potentially detrimental effects of adjuvant chemotherapy, or because they are relatively resistant to chemo, or a combination of these issues.

One of the most influential messages from a trial in which carbo/taxol was given to patients with resected stage IB lung cancer is that the patients with tumors 4 cm and larger seemed to benefit from chemo, while those with tumors smaller than 4 cm did not. This is still a controversial point: another important trial, known as BR.10, was led by NCI-Canada gave cisplatin/navelbine to patients with stage IB and II resected NSCLC and showed a 15% improvement in 5-year survival, but the publication showed that the benefit was only in the patients in the stage II category. Stage IB patients didn’t get the benefit with post-operative chemotherapy.

This past ASCO included a presentation of the longer-term, updated results for that BR.10 trial of adjuvant chemo vs. observation alone. These updated reports are really relevant, because we need to care about long-term survival, and more mature follow up of the IALT trial and some other work has shown that some of the early survival benefits may weaken with longer-term follow-up. In contrast, the more mature analysis from BR.10, with a median follow-up of 9 years, shows that the advantage with chemotherapy is still significant over time, with 5-year survival at 67% vs. 56%.

BR.10 Trial Mature OS Results

BR.10 Trial Mature OS Results

(Click on figure to enlarge)

What I found more interesting was the breakdown of the results within the stage IB category. As in the US-based CALGB study, there was a clear difference in outcomes for patients with tumors of 4 cm or larger compared to those for patients with smaller tumors.

BR10 Trial Stage IB OS by Tumor Size

BR10 Trial Stage IB OS by Tumor Size

The results aren’t statistically significant, but the study wasn’t designed to test differences in subgroups (tumor size) of subgroups (stage: IB vs. II). But living in the real world, we need to make treatment recommendations in which there are potentially harmful consequences of overtreatment as well as undertreatment. In other words, we can’t necessarily rely on the comfort of statistics to tell us exactly what to do and actually need to interpret the results ourselves. One very concerning factor is that in the BR.10 trial, not only was there no benefit for stage IB patients with smaller tumors, but there was actually a nearly significant detrimental effect of chemo. This is worse than was seen in the CALGB trial, in which the effect of chemo in this group was neutral. As in the CALGB trial, there was a very strong trend of a benefit in the stage IB patients with larger tumors on the BR.10 study.

We are coming to recognize increasingly that there are also molecular variables that may help us differentiate higher risk from lower risk cancers, independent of clinical stage, and more work is emerging on the biological discriminators. But in the meantime, exact stage and tumor size are emerging as consistent factors that should arguably impact our recommendations for adjuvant chemotherapy, and we are seeing that more treatment is not always better and in fact may be worse.

Overall, then, this is another example of the important ongoing theme of personalizing treatment recommendations to provide the most benefit for every individual patient. But I would now be very wary about recommending chemotherapy for a patient with a stage IB tumor that is smaller than 4 cm, at least outside of a clinical trial.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on